Teladoc Health (TDOC) Expected to Announce Quarterly Earnings on Wednesday

Teladoc Health (NYSE:TDOC) will likely be announcing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Teladoc Health to post earnings of ($0.19) per share and revenue of $635.3290 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 5:00 PM ET.

Teladoc Health Price Performance

Teladoc Health stock opened at $4.56 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. The stock has a market cap of $808.38 million, a price-to-earnings ratio of -3.56 and a beta of 2.12. The firm has a 50-day moving average of $6.17 and a two-hundred day moving average of $7.26. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $11.90.

Insider Buying and Selling

In other Teladoc Health news, insider Carlos Nueno sold 3,897 shares of Teladoc Health stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $29,188.53. Following the completion of the transaction, the insider owned 27,175 shares in the company, valued at approximately $203,540.75. This trade represents a 12.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Fernando M. Rodrigues sold 4,209 shares of Teladoc Health stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $7.48, for a total transaction of $31,483.32. The SEC filing for this sale provides additional information. Insiders sold a total of 33,288 shares of company stock valued at $251,684 over the last quarter. 0.58% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teladoc Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC boosted its stake in shares of Teladoc Health by 236.6% in the 4th quarter. Corient Private Wealth LLC now owns 37,692 shares of the health services provider’s stock valued at $264,000 after buying an additional 26,494 shares during the period. Mackenzie Financial Corp raised its holdings in Teladoc Health by 38.6% in the fourth quarter. Mackenzie Financial Corp now owns 165,550 shares of the health services provider’s stock valued at $1,157,000 after acquiring an additional 46,090 shares in the last quarter. Empowered Funds LLC raised its holdings in Teladoc Health by 1.9% in the fourth quarter. Empowered Funds LLC now owns 742,305 shares of the health services provider’s stock valued at $5,196,000 after acquiring an additional 14,029 shares in the last quarter. Voloridge Investment Management LLC lifted its stake in Teladoc Health by 42.8% in the fourth quarter. Voloridge Investment Management LLC now owns 997,427 shares of the health services provider’s stock worth $6,982,000 after acquiring an additional 299,086 shares during the last quarter. Finally, Polymer Capital Management US LLC grew its holdings in Teladoc Health by 32.0% during the 4th quarter. Polymer Capital Management US LLC now owns 22,443 shares of the health services provider’s stock worth $157,000 after acquiring an additional 5,443 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

Analysts Set New Price Targets

TDOC has been the topic of several analyst reports. Barclays initiated coverage on Teladoc Health in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 target price on the stock. Citigroup lowered their price target on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Friday, January 9th. Zacks Research downgraded shares of Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Teladoc Health in a research note on Monday, December 29th. Finally, Bank of America lowered their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Tuesday, November 25th. Three analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.12.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.